Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;12(10):585-92.
doi: 10.1038/nrurol.2015.232.

Gender differences in incidence and outcomes of urothelial and kidney cancer

Affiliations
Review

Gender differences in incidence and outcomes of urothelial and kidney cancer

Ilaria Lucca et al. Nat Rev Urol. 2015 Oct.

Erratum in

Abstract

A gender discrepancy exists in the incidence of both urothelial and kidney carcinomas, with more men presenting with these cancers than women. Men have a threefold greater risk of developing bladder cancer than women, but female gender has been identified as an independent adverse prognostic factor for both recurrence and progression of this disease. In particular, women with bladder cancer are often diagnosed with a higher tumour stage than men. Conclusive data on the influence of gender on outcomes of patients with upper tract urothelial carcinoma are currently lacking, although men seem to have a higher disease incidence, whereas survival outcomes might be independent of gender. Patients with renal cell carcinoma are more often men and they typically have larger tumours and higher stage and grade disease than women with this cancer. Smoking habits, tumour biology, occupational risk factors and sex steroid hormones and their receptors could have a role in these observed gender disparities. The majority of data support the theory that gender influences incidence and prognosis of urothelial and kidney cancers; men and women are different genetically and socially, making the consideration of gender a key factor in the clinical decision-making process. Thus, the inclusion of this variable in validated prognostic tables and nomograms should be discussed as a matter of importance.

PubMed Disclaimer

References

    1. Int J Cancer. 2015 Jul 1;137(1):238-42 - PubMed
    1. Cancer Res. 2006 Feb 15;66(4):2000-11 - PubMed
    1. Am J Hum Genet. 2004 Mar;74(3):399-402 - PubMed
    1. Carcinogenesis. 2014 Mar;35(3):651-61 - PubMed
    1. BJU Int. 2013 Nov;112(7):909-16 - PubMed